Repligen Corporation logo

Repligen Corporation (RGN)

Market Open
8 Dec, 07:15
140. 05
-0.65
-0.46%
- Market Cap
212.35 P/E Ratio
0% Div Yield
0 Volume
1.46 Eps
140.7
Previous Close
Day Range
140.05 140.05
Year Range
94.12 170
Want to track RGN and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 71 days

Summary

RGN trading today lower at €140.05, a decrease of 0.46% from yesterday's close, completing a monthly increase of 9.71% or €12.4. Over the past 12 months, RGN stock gained 1.74%.
RGN is not paying dividends to its shareholders.
The last earnings report, released on Nov 10, 2025, missed the consensus estimates by -0.42%. On average, the company has fell short of earnings expectations by -0.28%, based on the last three reports. The next scheduled earnings report is due on Feb 17, 2026.
The stock of the company had never split.
The company's stock is traded on 7 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).

RGN Chart

Repligen Corporation (RGEN) Presents at Evercore 8th Annual Healthcare Conference Transcript

Repligen Corporation (RGEN) Presents at Evercore 8th Annual Healthcare Conference Transcript

Repligen Corporation (RGEN) Presents at Evercore 8th Annual Healthcare Conference Transcript

Seekingalpha | 4 days ago
Repligen Corporation (RGEN) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript

Repligen Corporation (RGEN) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript

Repligen Corporation ( RGEN ) 7th Annual Wolfe Research Healthcare Conference November 18, 2025 12:40 PM EST Company Participants Jason Garland - CFO & Chief Compliance Officer Steven Chehames Conference Call Participants Douglas Schenkel - Wolfe Research, LLC Presentation Douglas Schenkel Wolfe Research, LLC All right. Good afternoon, everybody.

Seekingalpha | 2 weeks ago
Repligen Corporation (RGEN) Presents at Jefferies London Healthcare Conference 2025 Transcript

Repligen Corporation (RGEN) Presents at Jefferies London Healthcare Conference 2025 Transcript

Repligen Corporation ( RGEN ) Jefferies London Healthcare Conference 2025 November 18, 2025 8:30 AM EST Company Participants Olivier Loeillot - President, CEO & Director Conference Call Participants Matthew Stanton - Jefferies LLC, Research Division Presentation Matthew Stanton Jefferies LLC, Research Division Thanks. My name is Matt Stanton.

Seekingalpha | 2 weeks ago

Repligen Corporation (RGN) FAQ

What is the stock price today?

The current price is €140.05.

On which exchange is it traded?

Repligen Corporation is listed on NASDAQ (NGS).

What is its stock symbol?

The ticker symbol is RGN.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, no market cap data is available.

What is the earnings per share?

The EPS is 0.44.

When is the next earnings date?

The next earnings report will release on Feb 17, 2026.

Has Repligen Corporation ever had a stock split?

No, there has never been a stock split.

Repligen Corporation Profile

Electronic Equipment, Instruments & Components Industry
Information Technology Sector
Olivier Loeillot CEO
XFRA Exchange
US7599161095 ISIN
US Country
1,778 Employees
- Last Dividend
- Last Split
26 Mar 1990 IPO Date

Overview

Repligen Corporation is an innovative force in the biotechnological industry, primarily focusing on the development and commercialization of bioprocessing technologies and systems that play a crucial role in biological drug manufacturing. With a global reach that extends across North America, Europe, the Asia Pacific, and additional international markets, Repligen stands at the forefront of facilitating the production of biological drugs. The company, incorporated in 1981 and based in Waltham, Massachusetts, has established itself as a pivotal contributor to the biopharmaceutical and diagnostics sectors by offering a robust portfolio of products designed to enhance the efficiency and productivity of drug manufacturing processes. Through strategic collaboration agreements, such as with Navigo Proteins GmbH, Repligen continues to expand its technological arsenal, ensuring it remains synonymous with innovation and quality in the bioprocessing industry.

Products and Services

  • Protein A Ligands and Cell Culture Growth Factor Products: They serve as the binding components of Protein A affinity chromatography resins, crucial for purifying biologics, alongside products designed to enhance cell culture growth, thereby increasing the yield of bioprocesses.
  • Chromatography Products: This encompasses OPUS pre-packed chromatography columns for biologics purification, alongside smaller-scale columns used in process development, viral clearance, and process validation studies, reinforcing the versatility and efficiency of bioprocessing workflows.
  • ELISA Test Kits and CaptivA Resins: These are essential for the detection and quantification of various biological agents, with chromatography resins under the CaptivA brand further supporting the purification stages of drug manufacturing.
  • Filtration Products: The line includes XCell Alternating Tangential Flow systems for upstream perfusion and cell culture, TangenX cassettes, and KrosFlo systems for downstream processing like drug concentration and buffer exchange, alongside Spectra/Por dialysis products and ProConnex flow paths, showcasing a comprehensive range of solutions for biologic drug filtration needs.
  • Process Analytics Products: With slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands, Repligen offers innovative solutions for process analytics, enabling more efficient and accurate monitoring and optimization of bioprocessing parameters.

Contact Information

Address: Building 1
Phone: 781 250 0111